BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the

NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

Elicio Therapeutics, Inc. (Nasdaq: ELTX) ("Elicio" or the "Company"), a clinical-sta

BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the

LOS ANGELES--(BUSINESS WIRE)---- $ELTX--ELTX Investors Have Opportunity to Join Elicio Therapeutics,

NEW YORK, June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

Ladenburg Thalmann analyst Kevin DeGeeter assumes Elicio Therapeutics (NASDAQ:ELTX) with a Buy ra

Smith & Wesson (SWBI) shares rose in pre-market trading after posting strong Q4 results, beating

Elicio shares complete response data for ELI-002 7P in KRAS pancreatic cancer and plans combination

100% confirmed complete radiographic and complete metabolic responses in three patients who progress

Elicio Therapeutics reports mixed Phase 2 pancreatic cancer results, identifies key patient subgroup

US stocks gain on peace agreement with Iran, Nasdaq up 2%, Dow up 1.1%, S&P 500 up 1.54%. Tech s

US stocks rise on peace agreement with Iran, Dow up 600 points. Tech sector jumps, energy stocks dow

HC Wainwright & Co. analyst Robert Burns maintains Elicio Therapeutics (NASDAQ:ELTX) with a B

AMPLIFY-7P did not meet the pre-specified primary endpoint of disease-free survival ("DFS")

B. Riley Securities analyst Mayank Mamtani initiates coverage on Elicio Therapeutics (NASDAQ:ELTX

Preclinical results demonstrated that AMP-DNA adjuvants significantly enhanced both cellular and hum

HC Wainwright & Co. analyst Robert Burns reiterates Elicio Therapeutics (NASDAQ:ELTX) with a

Elicio Therapeutics (NASDAQ:ELTX) reported quarterly losses of $(0.65) per share which missed the an

U.S. stocks traded mixed this morning, with Dow Jones dropping around 20 points on Monday. Followin